A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological IntelligenceTM, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 21M | - | 34M | 59M | 35M |
| Net Income | -64M | -62M | -51M | -22M | -27M |
| EPS | $-0.59 | $-0.61 | $-0.51 | $-0.26 | $-0.33 |
| Free Cash Flow | -35M | -42M | 703K | -21M | -9.7M |
| ROIC | -21.9% | -21.6% | -16.1% | -6.5% | -11.5% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.13 | 0.19 | 0.23 | 0.30 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -69M | -75M | -69M | -27M | -36M |
| Operating Margin | -327.5% | - | -203.2% | -45.1% | -102.5% |
| ROE | -22.9% | -20.6% | -16.1% | -6.5% | -11.5% |
| Shares Outstanding | 144M | 102M | 99M | 86M | 82M |
| Metric | 2021 | 2022 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 35M | 59M | 34M | N/A | 21M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -36M | -27M | -69M | -75M | -69M |
| Op. Margin | -102.5% | -45.1% | -203.2% | N/A | -327.5% |
| Net Income | -27M | -22M | -51M | -62M | -64M |
| Net Margin | -77.8% | -37.8% | -148.2% | N/A | -301.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -11.5% | -6.5% | -16.1% | -21.6% | -21.9% |
| ROE | -11.5% | -6.5% | -16.1% | -20.6% | -22.9% |
| ROA | -8.9% | -5.3% | -13.5% | -17.7% | -20.6% |
| Cash Flow | |||||
| Op. Cash Flow | -5.7M | -3.6M | 2.3M | -40M | -35M |
| Free Cash Flow | -9.7M | -21M | 703K | -42M | -35M |
| Owner Earnings | -37M | -40M | -42M | -85M | -80M |
| CapEx | 4.1M | 17M | 1.6M | 1.9M | 602K |
| Maint. CapEx | 16M | 18M | 19M | 24M | 24M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 |
| D&A | 16M | 18M | 19M | 24M | 24M |
| CapEx/OCF | N/A | N/A | 70.0% | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 15M | 18M | 25M | 21M | 21M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -29M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 29M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.30 | 0.23 | 0.19 | 0.13 | 0.00 |
| Interest Coverage | -5087.0 | N/A | N/A | N/A | N/A |
| Equity | 234M | 341M | 315M | 288M | 277M |
| Total Assets | 304M | 421M | 375M | 326M | 310M |
| Total Liabilities | 70M | 80M | 61M | 38M | 32M |
| Intangibles | 260M | 251M | 239M | 222M | 222M |
| Retained Earnings | 0 | 11M | -39M | -101M | -101M |
| Working Capital | 2.0M | 99M | 72M | 53M | 53M |
| Current Assets | 23M | 125M | 95M | 68M | 68M |
| Current Liabilities | 21M | 26M | 23M | 15M | 15M |
| Per Share Data | |||||
| EPS | -0.33 | -0.26 | -0.51 | -0.61 | -0.59 |
| Owner EPS | -0.45 | -0.47 | -0.42 | -0.83 | -0.55 |
| Book Value | 2.86 | 3.97 | 3.17 | 2.83 | 1.93 |
| Cash Flow/Share | -0.07 | -0.04 | 0.02 | -0.39 | -0.28 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 81.9M | 85.9M | 99.3M | 101.7M | 144.0M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -2.5 |
| P/FCF | N/A | N/A | 864.1 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.5 | 0.9 | 1.9 | 1.3 | 0.8 |
| Price/Sales | 23.5 | 13.0 | 13.1 | N/A | 10.0 |
| FCF Yield | -1.2% | -6.6% | 0.1% | -11.4% | -16.8% |
| Market Cap | 816M | 314M | 607M | 365M | 210M |
| Avg. Price | 9.97 | 8.94 | 4.51 | 4.65 | 1.46 |
| Year-End Price | 9.96 | 3.66 | 6.12 | 3.59 | 1.46 |
OmniAb, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
OmniAb, Inc. (OABI) has a 5-year average return on invested capital (ROIC) of -13.9%. This is below average and may indicate limited pricing power.
OmniAb, Inc. (OABI) has a market capitalization of $210M. It is classified as a small-cap stock.
OmniAb, Inc. (OABI) does not currently pay a regular dividend.
OmniAb, Inc. (OABI) operates in the Services-Commercial Physical & Biological Research industry, within the Industrials sector.
OmniAb, Inc. (OABI) generated $-42 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
OmniAb, Inc. (OABI) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
OmniAb, Inc. (OABI) reported earnings per share (EPS) of $-0.61 in its most recent fiscal year.
OmniAb, Inc. (OABI) has a return on equity (ROE) of -20.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for OmniAb, Inc. (OABI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
OmniAb, Inc. (OABI) has a book value per share of $2.83, based on its most recent annual SEC filing.